Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention

David E. Gerber, Jodi B. Segal, M. Yair Levy, Joyce Kane, Richard J. Jones, Michael B. Streiff

Blood (2008) 112 (3): 504–510.

https://doi.org/10.1182/blood-2007-10-117051

Published: 2008

Journal Articles

Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes.

David E. Gerber, MD, Jodi B. Segal, MD, M. Yair Levy, MD, Joyce M. Kane, RN, Richard J. Jones, MD, Michael B. Streiff, MD

Blood (2007) 110 (11): 1628.

https://doi.org/10.1182/blood.V110.11.1628.1628

Published: 2007

Journal Articles

Impact of Killer Immunoglobulin Receptor (KIR) Ligand Incompatibility in Nonmyeloablative Bone Marrow Transplantation (BMT) from Haploidentical Donors.

Heather J. Symons, MD, M. Sue Leffell, PhD, Nancy D. Rossiter, Elizabeth Sugar, PhD, Leo Luznik, MD, Michele Phelps, Angelita Crawford, M. Yair Levy, MD, Richard J. Jones, MD, Ephraim J. Fuchs, MD

Blood (2006) 108 (11): 604.

https://doi.org/10.1182/blood.V108.11.604.604

Published: 2006

Journal Articles

Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy).

Heather J. Symons, MD, Leo Luznik, MD, Michele Phelps, Angelita Crawford, Katherine McIntyre, M. Yair Levy, MD, Richard J. Jones, MD, Ephraim J. Fuchs, MD

Blood (2006) 108 (11): 2859.

https://doi.org/10.1182/blood.V108.11.2859.2859

Published: 2006

Journal Articles

Therapeutic Anti-Tumor Immunity Mediated by Transiently Engrafting Allogeneic Lymphocytes: The “Allogeneic Effect” Revisited.

Heather J. Symons, MD, M. Yair Levy, MD, Jie Wang, MD, Xiaotao Zhou, MS, Ephraim J. Fuchs, MD

Blood (2005) 106 (11): 5255.

https://doi.org/10.1182/blood.V106.11.5255.5255

Published: 2005

Journal Articles

Low Incidence of CMV Reactivation and Infectious Morbidity and Mortality after Nonmyeloablative Haploidentical Bone Marrow Transplantation Incorporating Post-Transplantation Cyclophosphamide.

Heather J. Symons, MD, Xiaobu Ye, MD, Leo Luznik, MD, Michele Phelps, Angelita Crawford, M. Yair Levy, MD, Richard J. Jones, MD, Ephraim J. Fuchs, MD

Blood (2005) 106 (11): 3245.

https://doi.org/10.1182/blood.V106.11.3245.3245

Published: 2005

NARROW

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention

Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes.

Impact of Killer Immunoglobulin Receptor (KIR) Ligand Incompatibility in Nonmyeloablative Bone Marrow Transplantation (BMT) from Haploidentical Donors.

Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy).

Therapeutic Anti-Tumor Immunity Mediated by Transiently Engrafting Allogeneic Lymphocytes: The “Allogeneic Effect” Revisited.

Low Incidence of CMV Reactivation and Infectious Morbidity and Mortality after Nonmyeloablative Haploidentical Bone Marrow Transplantation Incorporating Post-Transplantation Cyclophosphamide.

Email alerts

ASH Publications

American Society of Hematology

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention

Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes.

Impact of Killer Immunoglobulin Receptor (KIR) Ligand Incompatibility in Nonmyeloablative Bone Marrow Transplantation (BMT) from Haploidentical Donors.

Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy).

Therapeutic Anti-Tumor Immunity Mediated by Transiently Engrafting Allogeneic Lymphocytes: The “Allogeneic Effect” Revisited.

Low Incidence of CMV Reactivation and Infectious Morbidity and Mortality after Nonmyeloablative Haploidentical Bone Marrow Transplantation Incorporating Post-Transplantation Cyclophosphamide.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only